Page 2 - Dtx Pharma News Today

HONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical...

Novartis’s acquisition of DTx Pharma brings a lead program for a rare disease with no FDA-approved therapies. But the deal could also help the pharma giant bring new RNA therapies to new places in the body, a top Novartis executive explained.

The acquisition of DTx Pharma by drug giant Novartis includes the potential for an additional $500 million payout depending on reaching certain pre-determined milestones

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

/PRNewswire/ -- DTx Pharma, invested and incubated by Viva BioInnovator (VBI), is a preclinical stage biotechnology company addressing the delivery challenges...

Outside of the upcoming Sandoz spinoff, Novartis also raised its full-year group guidance based on its performance in the first half of 2023.

BioPharma

DTx Pharma is a preclinical stage biotechnology company that focuses on developing siRNA therapies for neuroscience indications, leveraging its proprietary fatty acid...

By Cecilia Butini Novartis will buy U.S.-based biotechnology company DTx Pharma for $500 million plus additional payments when certain scientific milestones are completed, the Swiss pharma...

Novartis (NVS) has acquired DTx Pharma, a preclinical stage biotechnology company focused on leveraging its FALCON platform to develop siRNA therapies for neuroscience indications.